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We generated transgenic mice expressing bovine cel-
lular prion protein (PrPC) with a leucine substitution at codon 
113 (113L). This protein is homologous to human protein 
with mutation 102L, and its genetic link with Gerstmann–
Sträussler–Scheinker syndrome has been established. 
This mutation in bovine PrPC causes a fully penetrant, le-
thal, spongiform encephalopathy. This genetic disease was 
transmitted by intracerebral inoculation of brain homoge-
nate from ill mice expressing mutant bovine PrP to mice ex-
pressing wild-type bovine PrP, which indicated de novo gen-
eration of infectious prions. Our findings demonstrate that 
a single amino acid change in the PrPC sequence can in-
duce spontaneous generation of an infectious prion disease 
that differs from all others identified in hosts expressing the 
same PrPC sequence. These observations support the view 
that a variety of infectious prion strains might spontaneously 
emerge in hosts displaying random genetic PrPC mutations.
Transmissible spongiform encephalopathies (TSEs) are fatal neurodegenerative diseases that affect humans and 
animals and involve pathologic conversion of host cellular 
prion protein (PrPC) to a disease-related isoform (PrPSc), 
as proposed in the protein-only hypothesis (1). Depending 
on how these encephalopathies originate, TSEs are clas-
sified as sporadic, genetic, or infectious. Most have been 
experimentally transmitted and, with some exceptions, the 
presence of PrP resistant to proteinase K digestion (PrPres) 
is related to their infectivity (2–4).
Human genetic TSEs are caused by >30 autosomal-
dominant point mutations in the human prion protein gene 
(Prnp) and have been classified as Gerstmann–Sträussler–
Scheinker syndrome, familial Creutzfeldt–Jakob disease, or 
fatal familial insomnia (FFI), according to the clinical symp-
toms. Some of these genetic diseases have been transmitted 
to primates or rodents, although transmission rates were low 
in most instances (5–8). Regarding TSEs, pathogenic mu-
tations in Prnp are believed to predispose mutant PrPC to 
convert spontaneously to a pathogenic isoform (9–11).
Several transgenic mouse models confirmed that PrPC 
with mutations induces a spectrum of neurologic diseases 
with clinical or histologic features of TSEs (12–15). How-
ever, the crucial prediction that a disease-associated PrP 
mutation can spontaneously generate infectivity has only 
been demonstrated in mice carrying the mutation D177N, 
the mouse equivalent of the mutation associated with hu-
man FFI (16). Spontaneous appearance of infectivity has 
also been reported in transgenic mice expressing a mouse 
PrPC with 2 point mutations (170N and 174T) that subtly 
affect the structure of its globular domain (17).
The first described and most common Gerstmann–
Sträussler–Scheinker syndrome mutation causing ataxia is 
P102L (18,19). Bovine P113L, which has a leucine substi-
tution at codon 113, is homologous to human P102L and 
mouse P101L. Although bovine PrPC with the 113L muta-
tion has not been found in nature, it would be useful to 
establish whether this mutation could induce spontaneous 
generation of an infectious prion disease in a bovine PrP 
context. In this study, we analyzed the phenotype of trans-
genic mice expressing mutant 113L bovine prion protein 
(BoPrP) and the ability of these mice to generate de novo 
infectious prions in comparison with control mice express-
ing the wild-type protein.
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Materials and Methods
Ethics
Animal experiments were conducted in strict accor-
dance with recommendations in the guidelines of the Code 
for Methods and Welfare Considerations in Behavioral 
Research with Animals (Directive 86/609EC). All efforts 
were made to minimize detrimental effects on animals. Ex-
periments were approved by the Committee on the Ethics 
of Animal Experiments of the INIA Institute (permit no. 
CEEA2009/004).
Transgenic Mice
The open reading frame (ORF) of the bovine Prnp 
gene was isolated by PCR amplification and cloned in 
a pGEM-T vector as described (20). The ORF was mu-
tated by using the QuikChange II-XL Kit (Stratagene, 
La Jolla, CA, USA) with specific oligonucleotides 
(5 ′ -CGGTCAGTGGAACAAGCTCAGTAAGCC -
GAAAACC-3′  and 5′-GGTTTTCGGCTTACTGAGCTT-
GTTCCACTGACCG-3′) according to procedures of the 
manufacturer. The P113L-PrP ORF was excised from the 
cloning vector by using restriction enzyme XhoI and inserted 
into MoPrP.Xho vector (21), which was also digested with 
XhoI. This vector contains the murine PrP promoter and 
exon-1, intron-1, exon-2, and 3′-untranslated sequences. 
Transgenic mice were generated by microinjection of DNA 
according to a published procedure (22).
Neuropathologic Studies in Spontaneously Diseased 
113LBoPrP-Tg Mice
Brains were rapidly harvested from the skulls and fixed 
in 4% paraformaldehyde in phosphate buffer. Coronal slabs 
were embedded in paraffin and 5-μm sections of cerebrum, 
cerebellum, brain stem, and spinal cord were obtained by 
using a sliding microtome. De-waxed sections were stained 
with hemotoxylin and eosin, Congo red, or thioflavin, or 
processed for immunohistochemical analysis. Immunohis-
tochemical analysis for detection of glial fibrillary acidic 
protein (GFAP) and cleaved caspase-3 was conducted by 
using a modified labeled streptavidin technique (LSAB2-
System peroxidase; Dako, Glostrup, Denmark). The rabbit 
polyclonal antibody to GFAP (Dako) was used at a dilution 
of 1:600. Cleaved caspase-3 rabbit polyclonal antibody 
(D175, cell signaling) was used at a dilution of 1:50. Mi-
croglial cells were stained with the biotinylated lectin from 
Lycopericon esculentum (L-0651; Sigma, St. Louis, MO, 
USA) and used at a dilution of 1:100. PrP was immuno-
labeled with monoclonal antibody (mAb) 6H4 (Prionics, 
Schlieren, Switzerland) and used at a dilution of 1:30 in 
sections pretreated with 35% HCl for 2 min at 100°C and 
then with 96% formic acid for 10 min at room temperature. 
These procedures have been detailed elsewhere (23).
Mouse Transmission Studies
For transmission studies, we used the Tg110 mouse 
line (20) that expresses wild-type bovine-PrPC in a mouse 
Prnp null background. Inocula were prepared from brain tis-
sues as 10% (wt/vol) homogenates. Individually identified 
6–10-week-old mice were anesthetized and inoculated with 
2 mg of 10% brain homogenate in the right parietal lobe by 
using a 25-gauge disposable hypodermic needle. Mice were 
observed daily and neurologic status was assessed weekly. 
When progression of TSE was evident or evident at 650 
days postinoculation (dpi), animals were euthanized for 
ethical reasons. Once mice were euthanized, brains were 
collected, frozen, and analyzed by Western blotting. Sam-
ples fixed in buffered 10% formalin underwent histologic 
analysis, immunohistochemical analysis, or histoblotting. 
Spleens were frozen for Western blot analysis.
Western Blot Analyses of PrPres
Frozen mouse brain samples were prepared as 10% (wt/
vol) homogenates in 5% glucose in distilled water in grind-
ing tubes (Bio-Rad, Hercules, CA, USA) by using a TeSeE 
Precess 48 homogenizer (Bio-Rad) following the manu-
facturer’s instructions. Samples were analyzed by Western 
blotting as described (24). For immunoblotting experiments, 
mAbs Sha31 (25), 9A2 (26), 12B2 (26), Saf84 (25), and 
R145 (Vetyerinary Laboratories Agency, Weybridge, UK) 
were used at concentrations of 1 μg/mL. Sha31 recognizes 156 
YEDRYYRE163 epitope, 9A2 recognizes 110WNK112 epitope, 
12B2 recognizes 101WGQGG105 epitope, Saf84 recognizes 
175RPVDQY180 epitope, and R145 recognizes 231RESQUA235 
epitope of the bovine PrP sequence.
Histopathologic Analysis
All procedures involving brains from infected mice 
were performed as described (27). Samples were fixed in 
neutral-buffered 10% formalin (4% formaldehyde) before 
being embedded in paraffin. Once deparaffinated, 2-µm 
tissue sections were stained with hematoxylin and eosin. 
Lesion profiles of brains were established according to the 
standard method described by Fraser and Dickinson (28). 
For paraffin-embedded tissue blots, the protocol described 
by Andréoletti et al. (29) was used.
Results
Expression of 113LBoPrP in Transgenic Mice
Seven lines (founders) of 113LBoPrPC heterozygous 
transgenic mice carrying the endogenous murine Prnp gene 
(Prnp mu+/- 113Lbo+/-) were obtained. Lines 113LBoPrP-
Tg037 and 113LBoPrP-Tg009 were selected on the basis of 
their expression levels, and bred to homozygosity in a mu-
rine Prnp null background. To achieve this expression, se-
lected lines were crossed with Prnp null mice (Prnp mu-/-) to 
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achieve transgene-hemizygous lines (Prnp mu-/- 113Lbo+/-). 
Absence of the murine Prnp gene was determined by us-
ing PCR with specific primers. Transgene expression levels 
were then determined in brain homogenates by serial dilu-
tion and compared with PrPC levels found in bovine brain 
homogenates. Transgene expression levels for the two 
1-month-old mice with hemizygous Tg lines 113LBoPrP-
Tg037 and 113LBoPrP-Tg009 were found to be ≈3× and 
0.5×, respectively. Mutant 113LBoPrP expressed in 009 and 
037 transgenic lines showed an electrophoretic profile simi-
lar to that of wild-type bovine PrPC from BoPrP-Tg110 mice 
or cow brain, although only small differences in glycoform 
ratios were observed (Figure 1). Next, by crossing hemizy-
gous animals, we obtained transgene-homozygous animals 
(Prnp mu-/- 113Lbo+/+) (30).
Spontaneous Neurologic Disease in Transgenic Mice 
Expressing Mutant 113LBoPrP
Spontaneous neurologic disease developed in 113LBo-
PrP-Tg037 mice expressing mutant 113LBoPrP. These mice 
had reduced lifespans compared with either non-Tg (Prnp-/-) 
mice or transgenic mice expressing similar or higher levels 
of wild-type BoPrP (Table 1). However, disease did not de-
velop in 113LBoPrP-Tg009 mice expressing low levels of 
mutant protein, and these mice had survival times similar to 
non-Tg (Prnp-/-) mice or BoPrP-Tg110 mice. Onset of clini-
cal signs and survival times were dependent on the expres-
sion level of 113LBoPrP (Table 1) (i.e., transgene-homo-
zygous 113LBoPrP-Tg037 mice showed an earlier onset of 
clinical signs and reduced survival times than hemizygous 
mice of the same line). Neurologic alterations generally in-
volved motor impairment with ataxia affecting mainly the 
hind limbs. Mice showed a rough coat and prominent hunch 
at the early stages of clinical signs. Most mice had a wob-
bling gait and slight paralysis in the back limbs. Some mice 
had conjunctivitis and showed compulsive scratching in the 
head area. At the end stage of the disease, mice had highly 
restricted movement and lethargy. No signs of hyperactivity 
were detected in these mice.
Neuropathologic Alterations in Transgenic Mice  
Expressing Mutant 113LBoPrP
All 113LBoPrP-Tg037 mice at the terminal disease 
stage showed spongiosis in the cerebral cortex, thalamus, 
and hilus of the dentate gyrus, but not in the CA1 region 
of the hippocampus and granule cell layer of the dentate 
gyrus, compared with age-matched control BoPrP-Tg110 
mice (Figure 2). Marked granule cell loss, spongiosis in the 
molecular layer, granule cell layer, subcortical white mat-
ter, and Bergmann glia hypertrophy and hyperplasia were 
also observed in these mice at the terminal disease stage. 
However, at the early stages of clinical signs, no spongi-
form changes were found, although neuronal loss was ob-
served when 113LBoPrP-Tg037 mice were compared with 
age-matched control BoPrP-Tg110 mice. These findings 
were particularly evident in the hippocampus proper (in-
cluding hilus) and granular cell layer of the cerebellum.
Changes were more pronounced in animals with se-
vere clinical manifestations. Neurons with a shrunken 
cytoplasm and nucleus were observed in all 113LBoPrP-
Tg037 mice, and these appeared in the molecular layer 
of the cerebellum, hippocampus (mainly plexiform lay-
ers and hilus), thalamus, and pons. Morphologic PrP ag-
gregates, congophilic materials, or thioflavin-positive 
deposits were not detected in 113LBoPrP-Tg037 mice. 
Astrocyte gliosis was observed throughout the brain in 
113LBoPrP-Tg037 mice, even at the early stage of the 
disease. The number and size of reactive astrocytes in-
creased, as shown by immunolabeling with antibody 
against GFAP, in the cerebral cortex, hippocampus, stria-
tum, thalamus, cerebellum, and brain stem. Microglial 
proliferation, as visualized with Lycopericum esculentum 
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Figure 1. Immunoblots of brain 
extracts from hemizygous 
113LBoPrP-Tg037+/− 113LBoPrP-
Tg009+/− mouse lines compared 
with those of cow brain extract 
and BoPrP-Tg110 mouse brain 
extract. Brain homogenates were 
analyzed by Western blotting with 
monoclonal antibody 2A11 (30). 
Lane 1, 113LBoPrPTg-009; lane 2, 
113LBoPrPTg-037; lane 3, Cow; 
lane 4, BoPrPTg-110. Equivalent 
amounts of total protein were 
loaded into each lane. 113L, 
leucine substitution at codon 
113; BoPrP, bovine prion protein. 
Values on the right are molecular 
masses in kilodaltons.
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lectin, was evident in brains of 113LBoPrP-Tg037 mice 
but not in age-matched control mice.
Modification of Biochemical Properties of Bovine-PrPC 
by Mutation 113L
To explore changes in biochemical properties of mu-
tant 113LBoPrP, we solubilized brain homogenates from 
control BoPrP-Tg110, 113LBoPrP-Tg037, and 113LBo-
PrP-Tg009 mouse lines in extraction buffer and ultracen-
trifuged them at 100,000 × g for 1 h. Western blotting of 
soluble and insoluble fractions indicated differential bio-
chemical properties of mutant 113LBoPrP compared with 
wild-type BoPrP (Figure 3); the 113L mutation resulted in 
a more insoluble protein. This insolubility was detected in 
113LBoPrP-Tg037 and 113LBoPrP-Tg009 mouse lines. 
However, when the 113LBoPrP-Tg009 mouse line was 
compared with the other 2 mouse lines, the expression 
level was lower and insolubility was detectable only when 
an 8-fold equivalent brain tissue mass was used (Figure 3, 
panel B) to obtain equivalent PrP signal.
Insolubility was detected early in the lifespan (30 days 
after birth) of mice (Figure 3, panel C), which suggested 
that quantification of 113LBoPrP would reflect a cumula-
tive effect. PK resistance was not found in mutant 113LBo-
PrP or in wild-type BoPrP, which were digested at the PK 
concentration used (Figure 3).
Spontaneous Generation of Infectious Prions by 
113LBoPrP-Tg037 Mice
To test potential infectivity of brains of mutant 
113LBoPrP-Tg037 mice, we intracerebrally inoculated 
brain homogenates from sick animals into transgenic mice 
expressing wild-type bovine PrP (BoPrP-Tg110). In the 
first experiment (Table 2), we used a brain homogenate 
from a unique terminally sick animal. In this instance, neu-
rologic signs developed in only 1 of 5 (attack rate 20%) 
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Table 1. Onset of clinical signs and survival times for transgenic mice expressing different levels of mutant 113LBoPrP or wild-type 
BoPrP* 
Transgenic mouse line Transgene expression level† 
Onset of clinical signs, days  
SEM (no. diseased/no. tested) Death, days  SEM 
113LBoPrP-Tg009+/– 0.5× >550 (0/9) >550 
113LBoPrP-Tg009+/+ 1× >550 (0/10) >550 
113LBoPrP-Tg037+/– 3× 272  33 (10/10) 345  49 
113LBoPrP-Tg037+/+ 6× 187  18 (6/6) 223  47 
BoPrP-Tg110+/–‡ 4× >550 (0/6) >550 
BoPrP-Tg110+/+‡ 8× >550 (0/10) >550 
Non-Tg (Prnp–/–) 0× >550 (0/9) >550 
*BoPrP, bovine prion protein; 113L, leucine substitution at codon 113; +/–hemizygous for bovine prion protein (Prnp) gene; +/+, homozygous for bovine 
Prnp gene. All transgenic animals were murine Prnp/. 
†Relative to cattle PrP expression. 
‡This BoPrP transgenic mouse line has been described (20,22). 
 
Figure 2. Comparison between 
homozygous bovine prion protein 
(BoPrP)-Tg110+/+ control mice 
(panels A–D) and hemizygous 
113LBoPrP-Tg037+/− mice with 
end-stage disease (panels E–H) 
in parietal cortex (panels A and 
E), CA1 region of the hipocampus 
(panels B and F), dentate gyrus 
(panels C and G), and medial 
thalamus (panels D and H). 
Severe spongiosis is seen in the 
cerebral cortex, hilus ofdentate 
gyrus, and medial thalamus, 
but not in the CA1 area of the 
hippocampus and granule cell 
layer of the dentate gyrus. 113L, 
leucine substitution at codon 
113. Paraffin-embedded sections 
were stained with hematoxylin 
and eosin. Scale bar in panel H 
= 25 µm.
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inoculated Tg110  mice. This mouse died at 333 dpi and 
contained a considerable amount of PrPres in its brain, as 
shown by Western blot (Figure 4).
When brain homogenate from this mouse was rein-
oculated into 6 Tg110 mice (second passage), neurologic 
signs developed in all recipients, and these mice showed 
a shorter mean ± SEM incubation period (272 ± 38 dpi), 
which was suggestive of an increased infectious titer that 
was maintained in subsequent passages (Table 2). These 
results were confirmed in a second independent experi-
ment with a brain homogenate derived from a pool of 5 
terminally sick 113LBoPrP-Tg037 mice. In this instance, 
2 of 6 (attack rate 33%) inoculated mice were infected 
(Tg110 mice) (33% attack rate) and had incubation pe-
riods of 322 and 406 dpi, respectively. As in the first 
experiment, second passage (using a pool containing 
both mouse brains) produced an attack rate of 100% and 
a shorter incubation period (291 ± 23 dpi), which were 
maintained in subsequent passages (Table 2).
Brain homogenate from Tg110 mice expressing com-
parable amounts of wild-type BoPrP, as well as brain ho-
mogenate from healthy mice, was also used to inoculate 
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Figure 3. Host cellular prion protein 
(PrPC) solubility and proteinase K (PK) 
resistance studies in homozygous 
113LBoPrP-Tg037, 113LBoPrP-Tg009, 
and control BoPrP-Tg110 mice. Western 
blot analysis with monoclonal antibody 
2A11 of soluble (S) and insoluble (P) 
fractions obtained from mouse brain 
extracts (5% sarkosyl in phosphate-
buffered saline, pH 7.4, previously 
cleared by centrifugation at 2,000 × g) 
after ultracentrifugation at 100,000 × g 
for 1 h. P fractions were treated with 5 
μg/mL of PK (PK+) at 37°C for 60 min 
or left untreated (PK–). Panels A and 
B, show brain extracts from diseased 
113LBoPrP-Tg037 mice or from 500-day-
old 113LBoPrP-Tg009 and BoPrP-Tg110 
mice. Panel C shows brain extracts 
from 30-day-old mice. In panels A and 
C, equivalent amounts of brain material 
were solubilized, centrifuged, and loaded 
onto the gel. In panel B, an 8-fold (8×) 
equivalent brain tissue mass was loaded 
to obtain equivalent PrPC signals for 
the other 2 mouse lines. 113L, leucine 
substitution at codon 113; BoPrP, bovine 
prion protein. Values on the right are 
molecular masses in kilodaltons.
 
Table 2. Infectivity of 113LBoPrP-Tg037 mice brain homogenates in BoPrP-Tg110* 
Inoculum 
Mean  SEM survival time, days (no. diseased/no. tested)† 
First passage Second passage Third passage 
113LBoPrP-Tg037 (179 d old)‡ 330 (1/5) 272  38 (6/6) 252  23 (6/6) 
113LBoPrP-Tg037-pool (150–250 d old)§ 322, 406 (2/6) 291  23 (6/6) 255  14 (7/7) 
wtBoPrP-Tg110-pool (500–600 d old) >650 (0/12) >650 (0/12) NA 
Normal mouse brain (500–600 d old) >650 (0/12) >650 (0/12) NA 
Classical BSE-C (VLAPG817/00) ¶ 295  12 (6/6) 265  35 (6/6) NA 
Atypical BSE-H (CASE 03–2095)# 292  5 (6/6) 296  7 (6/6) NA 
Atypical BSE-L (02.2528)** 207  7 (6/6) 199  1 (6/6) NA 
*BoPrP, bovine prion protein; 113L, leucine substitution at codon 113; wtBoPrP, wild-type bovine prion protein; NA, not available; BSE, bovine spongiform 
encephalopathy. 
†Intracerebral inoculation with 2 mg brain tissue equivalent in BoPrP-Tg110+/+ (8× expression level). 
‡Brain homogenate from a unique terminally sick animal. 
§Brain homogenate from a pool of 5 terminally sick mice that died at 150–250 d of age. 
¶Brainstem homogenate of 1 cow naturally infected with classical BSE (RQ 225:PG817/00) supplied by the Veterinary Laboratories Agency (New Haw,  
#Data from Torres et al. (31). 
**Brainstem samples from naturally affected cows given a diagnosis of atypical BSE-L by the Agence Française de Sécurité Sanitaire des Aliments (Lyon, 
France). 
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uninfected mice, which served as negative controls. Neu-
rologic signs did not develop in any of the inoculated mice 
(Table 2). These mice were euthanized at 650 dpi and did 
not show any PrPres in their brains by Western blot.
For comparative studies, material from the brainstem 
of cows that contained classical bovine spongiform en-
cephalopathy (BSE), atypical BSE-H, and atypical BSE-L 
prions was also inoculated into mice by the same proce-
dure. These 3 inocula induced a typical neurologic disease 
after primary transmission and showed an attack rate of 
100% (Table 2). Survivals times of mice inoculated with 
brainstem of 113LBoPrP-Tg037 mice on second and third 
passages were similar to those produced by the classical 
BSE-C isolate (Table 2), as well as by other isolates re-
ported for the same Tg110 mouse line (20,22,32).
Properties of P113L-BSE Prion
Western blot analysis with mAb 9A2 against brain-
PrPres produced by BoPrP-Tg110 mice infected with the 
new 113L-BSE prion (Figure 4, panel A) showed a typical 
BSE PrP banding pattern characterized by small fragments 
(19-kDa fragment for the aglycosyl band) and prominent 
diglycosylated species in all challenged PrPres-positive 
mice. This result was indistinguishable from that produced 
by classical BSE-C prion in these mice but differed from 
that observed after inoculation with atypical BSE-H or 
BSE-L prions (Figure 4, panel A).
Further characterization of PrPres with other mAbs 
showed that the new 113L-BSE prion  was not recog-
nized by mAb 12B2 (Figure 4, panel B), whose epitope 
(101WGQGG105 according to the bovine PrP sequence) is 
known to be poorly protected from PK digestion (26,32) 
in the classical BSE-derived prion but well preserved in 
the atypical BSE-H prion (Figure 4, panel B) (31). Further-
more, PrPres immunolabeling with mAbs Saf84 and R145 
showed that mice infected with the new 113L-BSE prion, 
in contrast to mice infected with the H-type prion, did not 
show the characteristic PrPres band profile (4 bands) of cat-
tle BSE-H, but showed a PrPres-profile (3 bands) similar to 
that of the BSE-C prion (Figure 4, panels C, D).
Comparative study of PrPSc accumulation in spleen 
from Tg110-infected mice showed that mice infected with 
113L-BSE or BSE-C prions consistently showed  positive 
results for presence of PrPres by Western blot. In contrast, 
no PrPSc deposits were detected in mice infected with either 
BSE-L or BSE-H prions. Similar results were obtained in 
subsequent passages.
We next examined vacuolation and PrPSc distribution 
in the brain, which are known to vary by strains/TSE pri-
ons (28,33). In general, we observed that PrPSc deposition 
patterns in brains of 113L-BSE–infected mice were differ-
ent from mice infected with BSE-H or BSE-L prions, but 
these overlapped mostly with those infected with BSE-C 
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Figure 4. Comparative Western blot analyses of brain prion protein 
resistant to proteinase K digestion (PrPres) from BoPrP-Tg110 
mice infected with bovine spongiform encephalopathy (BSE)-C, 
113L-BSE, BSE-L, and BSE-H prions. Mice infected with newly 
generated 113L-BSE prion at first (P1), second (P2), and third (P3) 
passages are compared with mice infected with BSE-C (P1) (lane 
4); BSE-L (P1) (lane 5); and BSE-H (P1) (lane 6) prions. Each panel 
was identified by using the monoclonal antibody (mAb) listed at the 
bottom left. The same quantities of PrPres were loaded in all lanes. 
BoPrP, bovine prion protein; 113L, leucine substitution at codon 113. 
Values on the right are molecular masses in kilodaltons.
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prion (Figure 5). However, 113L-BSE–infected mice at the 
terminal stage of disease showed only spongiform changes 
that remained limited to the thalamus even after 3 passages 
(Figure 6). This finding was in contrast with lesion pro-
files observed in the mice infected with BSE-C, BSE-H 
or BSE-L prions (Figure 6) in which substantial vacuolar 
changes were observed in various brain areas. These results 
indicate that 113L-BSE is an authentic infectious prion that 
phenotypically differs from BSE-H and BSE-L prions but 
has biochemical characteristic and histopathologic features 
similar to those of the classical BSE-C prion.
Discussion
We showed that the 113L mutation in the bovine Prnp 
gene gives rise to a spontaneous neurodegenerative disease 
when expressed in transgenic mice. Neurologic symptoms 
of ataxia, rigidity, and lethargy accompanied by spongi-
form degeneration throughout the brain spontaneously de-
velop in these mice. The rate at which illness progresses 
is related to expression levels of the mutant 113LBoPrP 
(Table 1). Neurologic alterations did not develop in several 
mouse lines expressing similar or higher levels of wild-
type bovine PrPC during their lifespan, which is similar to 
observations in wild-type mice (Table 1) (20). Although 
the mechanism inducing the disease is unclear, we suggest 
that the 113L mutation in bovine PrPC could give rise to 
a different structure with respect to wild-type PrPC, which 
shows reduced solubility (Figure 3). Enhanced aggregation 
of mutant PrP could affect the appearance of the disease. 
Other mutations in the Prnp gene have also been related 
to enhanced aggregation of the mutant PrP in transgenic 
mice (12–14,34). However, the mechanisms through which 
these mutations may influence the aggregation properties 
of PrPC are unclear.
In previous studies, overexpression of murine PrP car-
rying the 101L mutation (equivalent to human 102L and 
bovine 113L mutations) led to spontaneous neurodegenera-
tive disease in mice (15,35,36). However, when this mu-
tation was introduced into the murine Prnp gene by gene 
targeting, mice homozygous for the 101L mutation showed 
no spontaneous spongiform encephalopathy (37). As pro-
posed by Manson et al., the lifespan of a mouse carrying 
only 1 or 2 copies of the mutant gene is insufficiently long 
enough to enable the stochastic event that makes TSE oc-
cur (37). Transgenic mice expressing high levels of human 
PrPC carrying the familial 101L mutation were reported to 
be free of disease (38). These results suggest that an equiv-
alent mutation in PrPs from different species might have 
different structural consequences. A possible explanation 
is that species-specific interaction sites for PrP cofactors or 
chaperones are required, and that in mice they are compat-
ible for bovine PrP but not for human PrP.
We also show that spontaneous neurodegenerative dis-
ease induced by the single 113L amino acid substitution is 
transmissible to mice expressing wild-type bovine PrPC, in-
dicating spontaneous generation of infectious prions. Trans-
missibility of this genetically initiated disease to mice not 
carrying 113L mutations provides crucial support for a caus-
al link between PrP misfolding and the spontaneous genera-
tion of a transmissible prion. Whether the small amount of 
insoluble PrP we detected in brain homogenates (Figure 3) 
constitutes the infectious prion in our mice, or some other as 
yet uncharacterized species, remains to be determined.
Several transgenic mouse models expressing PrP with 
various familial mutations have been reported (12–14,34).
Most of these transgenic mouse models have confirmed that 
the presence of these mutations triggers spontaneous dis-
ease, but spontaneous generation of a transmissible prion 
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Figure 5. Immunochemical analysis of paraffin-embedded tissue blots of representative coronal sections of the hippocampus, showing 
deposition patterns of abnormal isoform of host-encoded prion protein in brains from BoPrP-Tg110 mice infected with bovine spongiform 
encephalopathy (BSE)-C (A), 113L-BSE (B), BSE-H (C), and BSE-L (D) prions. BoPrP, bovine prion protein; 113L, leucine substitution at 
codon 113. Monoclonal antibody Sha31 stained by using the procedure of Andréoletti et al. (29). Original magnifications ×20. 
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has only been reported for mutation D178N, associated 
with human FFI (16). This study reported the spontane-
ous appearance of infectivity in knock-in mice carrying the 
mouse-equivalent D177N mutation. Spontaneous infectiv-
ity has also been reported in transgenic mice expressing a 
mouse PrP with 2 point mutations (170N and 174T), which 
subtly affect the structure of its globular domain (17).
The new 113L BSE prion generated shares some phe-
notypic features with the classical BSE-C prion when in-
oculated in the same Tg110 mouse line according to vari-
ous criteria: 1) apparent molecular mass of PrPres, 2) PrPres 
glycosylation pattern, 3) lack of immunoreactivity with mAb 
12B2, 4) pattern of labeling with mAbs Saf84 and R145, 5) 
detectable PrPres in spleens of infected animals, and 6) spa-
tial distribution of PrPres in brain. However, the vacuolation 
profile in brain was distinct from those of all known bovine 
prion strains (classical BSE-C, atypical BSE-H, and atypi-
cal BSE-L prions). These differences were maintained after 
subsequent passages, indicating that the novel prion, spon-
taneously produced by transgenic mice expressing mutant 
113LBoPrP, is distinct from all known bovine prion strains, 
although it shares many phenotypic features with the classi-
cal BSE-C prion.
These observations demonstrate that mutations in 
bovine PrP can result in spontaneous generation of infec-
tious prion diseases and support the hypothesis of a ge-
netic origin for the epidemic BSE prion. Different features 
exhibited by the new 113L-BSE prion, compared with 
those of the classical BSE prion, suggest that if the origin 
of BSE was genetic, it is unlikely that the causal mutation 
would be related to the 113L mutation. However, slight 
phenotypic differences observed could be the results of 
evolution of the epidemic BSE prion in field conditions 
in cattle, which must be different from those of our trans-
genic mouse model. Although BoPrP with the 113L muta-
tion has not been found in nature, a potential pathogenic 
mutation (E211K) within PrP has been recently reported in 
a cow with an H-type BSE phenotype (39). This mutation 
is equivalent to a common mutation (E200K) in humans, 
which is associated with genetic TSEs.
Spontaneous appearance of infectivity reported in 
transgenic mice expressing a mutated BoPrP and in mice 
expressing mutated mouse PrP reported by Stöhr et al. 
(40) supports the hypothesis that infectious TSE prions, 
could originate by a random genetic mutation that can in-
duce de novo generation of infectious prions, and that this 
mechanism could constitute a source of prion diversity. 
These considerations enable us to hypothesize that the BSE 
epidemic could have begun by a random genetic mutation 
that was able to generate de novo infectious prions, which 
were included in meat and bone meal fed to cattle and then 
broadly expanded in the cattle population. According to 
this hypothesis, a key strategy for controlling BSE would 
involve preventing cows from consuming products from 
cows with spontaneous cases of BSE.
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